PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma

• Status: Recruiting
• Trial end date: 2025-10-30

Summary

To learn about the effects of brentuximab vedotin and pembrolizumab in combination with doxorubicin and dacarbazine when given to patients who have Stage II cHL with bulky mediastinal disease or advanced cHL (Stage III or IV) and who have not received treatment for the disease.

• Phase: Phase 2

Details

• Lead Sponsor: M.D. Anderson Cancer Center
• Collaborators: Merck Sharp & Dohme LLC; Seagen Inc.
• Treatments: Brentuximab Vedotin; Dacarbazine; Doxorubicin; Liposomal doxorubicin; Pembrolizumab